Baird Maintains Outperform on CVS Health, Raises Price Target to $94

Benzinga Newsdesk www.benzinga.com Positive 90.0%

Neg 0% Neu 0% Pos 90%

Baird analyst Michael Ha maintains CVS Health (NYSE:CVS) with a Outperform and raises the price target from $92 to $94.

Comments

No comments yet. Be the first!